UBS O'Connor’s Maravai LifeSciences MRVI Stock Holding History

UBS O'Connor’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-75,065	Closed	-$3.68M	–	981
2021 Q3	$3.68M	Buy	+75,065	New	+$3.66M	0.03%	382

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

UBS O'Connor's MRVI Position: Q4 2021 in Review

UBS O'Connor sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 75,065 shares — an estimated $3.68M sold.

UBS O'Connor first reported a position in MRVI in Q3 2021 and held it in 1 quarter. The position peaked at $3.68M in Q3 2021. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

UBS O'Connor reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
UBS O'Connor sold 75,065 Maravai LifeSciences shares in Q4 2021, an estimated $3.68M.
UBS O'Connor first reported a position in Maravai LifeSciences in Q3 2021 and held it in 1 quarter.
UBS O'Connor's Maravai LifeSciences position peaked at $3.68M in Q3 2021.
229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.